Cantor Fitzgerald initiated coverage of Innoviva (INVA) with an Overweight rating and $26 price target
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INVA:
- Innoviva announces zoliflodacin NDA granted Priority Review by FDA
- Innoviva Specialty Therapeutics announces FDA accepts NDA for zoliflodacin
- Innoviva Elects Board Members and Approves Compensation
- Innoviva subsidiary announces U.S. commercial availability of ZEVTERA
- Innoviva’s Strong Q1 2025 Performance and Strategic Progress